Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Among authors: clemons m. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.
Goss PE, Strasser K, Marques R, Clemons M, Oza A, Goel R, Blackstein M, Kaizer L, Sterns EE, Nabholtz JM, De Coster R, Crump M, Abdolell M, Qi S. Goss PE, et al. Among authors: clemons m. Breast Cancer Res Treat. 2000 Nov;64(2):177-88. doi: 10.1023/a:1006480504790. Breast Cancer Res Treat. 2000. PMID: 11194453 Clinical Trial.
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Freedman O, et al. Among authors: clemons m. Breast Cancer Res Treat. 2009 Nov;118(2):377-83. doi: 10.1007/s10549-009-0452-8. Epub 2009 Jun 24. Breast Cancer Res Treat. 2009. PMID: 19551499
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Ellard SL, et al. Among authors: clemons m. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687332 Clinical Trial.
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF. Trudeau ME, et al. J Clin Oncol. 2009 Dec 10;27(35):5906-10. doi: 10.1200/JCO.2009.22.7504. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858391 Clinical Trial.
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Wong NS, et al. Among authors: clemons m. J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026801 Clinical Trial.
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard KI, Leighl NB. Taylor SK, et al. Among authors: clemons m. Oncologist. 2010;15(8):810-8. doi: 10.1634/theoncologist.2010-0081. Epub 2010 Aug 3. Oncologist. 2010. PMID: 20682606 Free PMC article. Clinical Trial.
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, Iscoe N, Gelmon K. Clemons M, et al. Breast Cancer Res Treat. 2010 Nov;124(1):177-86. doi: 10.1007/s10549-010-1152-0. Epub 2010 Sep 3. Breast Cancer Res Treat. 2010. PMID: 20814815 Clinical Trial.
409 results